Interpretation of key updates in the Chinese Society of Clinical Oncology clinical prac-tice guidelines for pancreatic cancer(2024)
10.12354/j.issn.1000-8179.2025.20250466
- VernacularTitle:《CSCO胰腺癌诊疗指南(2024)》更新要点解读
- Author:
Miao YANGYANG
1
;
Fan SONGSONG
1
;
Peng RUI
1
;
Cao JUN
1
;
Zhang JIAHAO
1
;
Bai DOUSHENG
1
Author Information
1. 扬州大学附属苏北人民医院肝胆外科(江苏省 扬州市 225001)
- Publication Type:Journal Article
- Keywords:
pancreatic cancer;
diagnosis and treatment guidelines;
guideline updates;
multidisciplinary collaboration;
Chinese Society of Clinical Oncology(CSCO)
- From:
Chinese Journal of Clinical Oncology
2025;52(9):433-437
- CountryChina
- Language:Chinese
-
Abstract:
With the rapid advancements in pancreatic cancer diagnosis and treatment research,the Chinese Society of Clinical Oncology(CSCO)has released two editions of pancreatic cancer diagnosis and treatment guidelines in 2022 and 2024.The present article systematic-ally compares the differences between the two editions in terms of diagnostic stratification,treatment pathways,and supportive manage-ment.By integrating insights from cutting-edge international research,the scientific rationale and clinical value of the underlying guideline revisions are explored.Clinicians are encouraged to adopt the new guidelines to dynamically assess the biological characteristics and treat-ment tolerance of patients,thereby formulating personalized diagnosis and treatment plans that ultimately lead to the synergistic enhance-ment of both survival benefits and quality of life for patients.
